ADDIA Proof-of-Performance Clinical Study

Inclusion Criteria: For all groups: * Female and male subjects aged 40 to 85 years. * Dated and signed informed consent by the subject (or its legal representative if applicable in accordance with the local regulations). * AD, NAD patients and control subjects will be age-matched and mean age similar in the three groups. * Able to comply with all study procedures. For AD group: * Diagnosis of AD: typical and atypical AD. * MMSE score (measured in the last 3 months): \< 21 for patients with moderate to severe AD. MMSE score \> 21 in subjects with mild AD with sporadic or a familial form of AD due to mutation in APP or PSEN1 or PSEN2 genes. * FCSRT, MoCA tests (MoCA measured in the last 3 months). * Neuroimaging compatible with a diagnosis of AD: * At least quantitative volumetric structural MRI: volumes of hippocampus and cortical areas. * Visual semi-quantitative MRI if practiced shall show medial temporal lobe atrophy (MTA) and parietal atrophy with visual rating (semi-quantitative) on the MTA-score (e.g. Scheltens' scores 0-4). MTA score must be ≥ 2 in patients aged 40-75 years and ≥ 3 in patients aged above 75 years. For patients younger than 60 years, and with familial form of AD, who may have normal MTA-scores, Koedam score (0-3) for Parietal Atrophy showing atrophy of the precuneus characteristic of AD may be used with a Koedam score from 1 to 3. Other neuroimaging data (retrospectively available) including PET Amyloid scan and FDG PET are desired if practiced…